Pazopanib: interakcje
Pazopanib (Votrient): 257 udokumentowanych interakcji w indeksowanych przez nas etykietach FDA i kartach informacyjnych. Poważne: 148, umiarkowane: 107, niewielkie: 2, pary, dla których etykieta nie zgłasza istotnej interakcji: 0. Każda pozycja poniżej cytuje zdanie, na którym się opiera. Ta strona leku to punkt wyjścia, a nie rozstrzygnięcie dla indywidualnej sytuacji.
Interakcje z etykiety
Poważne interakcje (148)
Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (etykieta leku Pazopanib, Interakcje z innymi lekami)
If concomitant administration with a gastric acid-reducing agent cannot be avoided, consider short-acting antacids in place of PPIs and H2-receptor antagonists. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
Umiarkowane interakcje (107)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Concomitant Use of Simvastatin Concomitant use of VOTRIENT and simvastatin increases the risk of ALT elevations [see Drug Interactions (7.3)] . (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
- LomitapidUmiarkowana
…Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology (12.3) ] . (etykieta leku Lomitapid, Interakcje z innymi lekami)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Clinical trials of VOTRIENT in combination with pemetrexed and lapatinib were terminated early due to increased toxicity and mortality. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Concomitant Use of Simvastatin Concomitant use of VOTRIENT and simvastatin increases the risk of ALT elevations [see Drug Interactions (7.3)] . (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Wzmianki o niewielkim znaczeniu (2)
- BewacyzumabNiewielka
Thrombotic Microangiopathy Thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), occurred in clinical trials of VOTRIENT as monotherapy, in combination with bevacizumab, and in combination with topotecan. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
- TopotekanNiewielka
Thrombotic Microangiopathy Thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), occurred in clinical trials of VOTRIENT as monotherapy, in combination with bevacizumab, and in combination with topotecan. (etykieta leku Pazopanib, Ostrzeżenia i środki ostrożności)
Sprawdź, jak Pazopanib łączy się ze wszystkim, co przyjmujesz. Dodaj całą listę; wszystkie pary są sprawdzane jednocześnie.
Otwórz w wyszukiwarceTo nie jest porada medyczna. Stopień nasilenia odzwierciedla sformułowania etykiety, a nie indywidualne okoliczności. Oznaczenie „poważna” może dotyczyć połączenia stosowanego rutynowo pod nadzorem, a „niewielka” może mieć znaczenie przy dużych dawkach. Należy zapytać farmaceutę.